Basic Information
Description
We did a comparison for B-hPD-L1 MC38(310685), B-hPD-L1 MC38 plus (310699) and B-hPD-L1 low MC38(310889).
-
General information of three versions of PD-L1 humanized MC38 cell lines
-
Reasons for using different versions at home and abroad:
There is a luciferase expressed in B-hPD-L1 MC38 plus. But scientists in the Boston lab were concerned that the luciferase expression might have an effect on the cell line. So they chose to use the version of B-hPD-L1 MC38 without luciferase expression. -
In vivo efficacy evaluation
-
-
TILs detection
-
-
Summary
-
Summary from this experiment：
B-hPD-L1 MC38：The efficacy is the most sensitive. Percentages of all the TILs detected were dose-dependent, except for the change trend of Th cells contrary to the theory. The expression level of PD-L1 in untreated group was high. But it was reduced significantly in the drug treated group.
B-hPD-L1 MC38 plus: The efficacy was slightly worse than that of B-hPD-L1 MC38. There was no significant dose-dependent changes in all the TILs detected. PD-L1 was expressed at the highest level, but was not dose-dependent；
B-hPD-L1 low MC38：The low-dose group was the least sensitive among the three cell lines. The efficacy of the high-dose group was similar to that of B-hPD-L1 MC38. Total T cells and Tregs in TILs tended to be dose-dependent, and there were no significant changes in other cells. Expression level of PD-L1 was the lowest and was not dose-dependent.Conclusion：
According to the efficacy and TILs detection results of this experiment, B-hPD-L1 MC38 cells are the most sensitive to Keytruda (pembrolizumab).
